drugset / Trial / NCT00161954

Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years

NCT00161954 ↗

Phase 4 Completed Pfizer
Non-randomizedSingle-groupOpen-labelPrevention

Summary

The objective of this study is to establish the earliest time point at which vaccines are expected to show seropositive antibody levels after vaccination with FSME-IMMUN 0.5 mL using a rapid immunization schedule (2 vaccinations administered 12 +/- 2 days apart.

Timeline

Start
2004-03
Primary completion
—
Completion
2004-05

Drugs

EvaluationDrugModalityDoseRoute
Subject FSME-IMMUN Vaccine 0.5 ml —